FINAL PROGRAMME FOR RHEUMATOLOGY RESEARCH - 28 February - 2 March 2019 - Lyon, France - EWRR
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
39TH EUROPEAN WORKSHOP
FOR RHEUMATOLOGY RESEARCH
28 February - 2 March 2019 — Lyon, France
FINAL PROGRAMME
www.ewrr.org
UCB: Into the future
with expertise
We are a global biopharmaceutical
company with 7,500 passionate
employees providing innovative and
differentiated solutions that address
the unmet needs that exist for
millions of patients.
Meeting patients’ unmet needs
TODAY
We have helped to positively change
hundreds-of-thousands of lives
through our innovative products
and solutions.
To date our focus is on creating
value for people living with…
Immunological and neurological
conditions:
• Epilepsy
• Rheumatic diseases
• Psoriatic diseases, now
including plaque psoriasis
Looking ahead…
We continue to demonstrate our
commitment to patients through
deepening our understanding of
their experiences, ensuring
treatments and support programs
provide them with valuable, holistic,
and tailored solutions
HQ/0119/CI/00001. January 2019
UCB Global Communications
© UCB 2019. All rights reserved.
CONTENT
PRESENTING EWRR 2019 4
• Welcome address from meeting organiser 4
• Committees 5
• Meeting venue and location 5
• General information 8
PROGRAMME OVERVIEW 10
• Thursday 28 February 2019 10
• Friday 1 March 2019 11
• Saturday 2 March 2019 11
PROGRAMME - THURSDAY 28 FEBRUARY 2019 12
PROGRAMME - FRIDAY 1 MARCH 2019 14
PROGRAMME - SATURDAY 2 MARCH 2019 17
POSTERS
- P001 - P011 Autoimmunity 1 19
- P012 - P023 Autoimmunity 2 19
- P024 - P034 Autoimmunity 3 21
- P035 - P043 Autoimmunity 4 21
- P044 - P052 Autoimmunity 5 22
- P053 - P066 Cell signalling and gene regulation 1 23
- P067 - P078 Cell signalling and gene regulation 2 24
- P080 - P085 Cell-cell interactions 26
- P086 - P094 Cytokines with focus on IL-17 and IL-17 26
producing cells 1
- P095 - P103 Cytokines with focus on IL-17 and IL-17 27
producing cells 2
- P104 - P109 Genes & environment 28
- P110 - P124 Mesenchymal cells 29
- P125 - P135 Novel therapies 1 30
- P136 - P147 Novel therapies 2 31
- P148 - P161 Systemic effects on inflamation 1 32
- P162 - P175 Systemic effects on inflamation 2 34
TRAVEL BURSARIES 37
SPONSORS 39
OFFICIAL BODIES 40
VENUE PLAN 42
3
PRESENTING EWRR 2019
WELCOME ADDRESS FROM MEETING ORGANISER
Dear Friends,
Bienvenue à Lyon, and welcome to the 39th European Workshop on Rheumatology
Research (EWRR). The meeting will start at 1.30 pm, but you are welcome to attend the
study groups in the morning.
As a result of my first message, you did a good job! We got more than 170 posters with a
young investigator as first author. All abstracts including those with oral presentation will
be presented as poster. The poster tour will take place Thursday after the last presentations
and before the networking event. Many poster tour leaders are ready, so everyone will have
the opportunity to present. This will be your chance to get a prize at the end of the meeting!
Out of the abstracts, some were selected for oral presentations. Here again the rule is that
the first author on the abstract will indeed present. Please make sure you stay on time. To
have more short oral presentations, the number of keynote presentations at the beginning
of the sessions has been reduced. It was indeed a great satisfaction that all the invited
speakers have immediately said “yes, I come”.
Planning the future is a key concern for most of the young still in training, although this
remains true later. As an experiment, during the Friday lunch break will take place a “meet
the experts” session, an open discussion with experts for different fields including basic
and clinical research in academia and industry, also publishing. Many experts have agreed
to run small groups to clarify all your questions. So, take some time on selecting the key
points you want to be clarified.
In addition to developing personal interactions for science and research, Lyon is also a
great place for happy life. We have selected typical examples of the cuisine of Lyon. The top
event will be the official dinner at the Hotel de Ville, city hall of Lyon, a building impressive
from the outside and even more the inside, specifically combined with another exposure
to fine cuisine.
Bon séjour, bon congrès,
With my best regards,
Professor Pierre Miossec
Clinical Immunology and Rheumatology
Immunogenomics and inflammation research unit
University of Lyon
miossec@univ-lyon1.fr
4
COMMITTEES
CONGRESS CHAIR
Pierre Miossec (FR)
SCIENTIFIC COMMITEE
Florence Apparailly (FR) Christian Jorgensen (FR)
Natasha Bessis (FR) Rick Lories (BE)
Marie-Christophe Boissier (FR) Hubert Marotte (FR)
Maxime Breban (FR) Caroline Ospelt (CH)
Gilles Chiocchia (FR) Costantino Pitzalis (UK)
Carlo Chizzolini (CH) Frederique Ponchel (UK)
Olivier Distler (CH) Jean Roudier (FR)
Dirk Elewaut (BE) Georg Schett (DE)
Cem Gabay (CH) Guy Serre (FR)
Arnaud Hot (FR)
LOCAL ORGANISING COMMITEE
Frédéric Coutant Marie Miossec
Samira Filali Melissa Noack
Arnaud Hot Julie Racinet
Hubert Marotte Marie-Nathalie Sarda
LOCAL WORKSHOP ORGANISER
EWRR 2019 c/o MCI Suisse SA
Rue du Pré-Bouvier 9 - 1242 Satigny - Switzerland
MEETING VENUE AND LOCATION
The 39th European Workshop for Rheumatology Research will take place at the
International Congress Center in Lyon, France.
50 Quai Charles de Gaulle
69463 Lyon
FRANCE
5
HOW TO GET THERE
By public transportation from the train stations
From the train station Part-Dieu, take bus line C1, bringing you in 15 minutes to
the congress center. Get off at the stop: Cité international
From the train station Perrache, take metro line A to Cordeliers and then bus line
C5 to the congress center, get off at the stop: Cité international
Check out all available connections on www.tcl.fr/en
ABOUT LYON
The Rhône region never leaves anyone indifferent – the contrasts of its landscapes
and Beaujolais vineyards constantly surprise.
Located at the confluent of the Rhône and the Saône, Lyon is proud of its 2000
years of history.
Once Lugdunum, capital of the Gauls, now Lyon, an international metropolis,
France’s second city proposes an original trip back in time and through cultures.
UNESCO has recognised the exceptional nature of Lyon by listing its historical site
as a World Heritage. Gastronomy, culture, nature, sport...
Lyon and the Rhône region offer visitors a warm welcome, surprising and delighting
them with their rich resources, festive atmosphere and carefully preserved quality
of life.
SIGHT SEEING
Visitors can take a unique journey through time and across cultures, by strolling
down its narrow streets, crossing its “traboules“ (narrow secret passages), walking
along its bustling docks, passing through its impressive squares, and seeing over
200 sites illuminated at night.
Outstanding museums, a dynamic cultural life, busy clubbing and drinking scenes,
a thriving university and fantastic shopping lend the city a distinctly sophisticated
air, while adventurous gourmets can indulge in their wildest gastronomic fantasies.
Don’t leave the city without sampling some Lyonnais specialties in a “bouchon” –
the quintessential Lyon experience.
EATING-OUT
The happiest of all visitors are the ones who journey here to sample the famous
cuisine. France’s most renowned chef, Paul Bocuse hails from Lyon. His celebrated
three-star Michelin restaurant is a top destination for gourmands. The legendary
Lyonnais gastronomy can also be enjoyed all over Lyon at “bouchons” evocative
little brasseries.
6
Our promise to people living with rheumatoid disease 140 years. That’s how long we have worked tirelessly to discover medicines that meet real needs. Finding ways to make a true difference. No matter the odds. From insulin to the discovery of treatments in depression and cancer, we have pioneered breakthroughs against some of the world’s most stubborn and devastating diseases. Our philosophy? Listen and understand. Our commitment? Create innovative medicines and practical solutions. Our passion? Help people live longer, healthier and more active lives. Rheumatic diseases are uncompromisingly complex. They can have a devastating impact on people’s lives. That’s why we are determined to fight them. Our heritage and expertise fuels that fight. © Eli Lilly and Company Limited. ALL RIGHTS RESERVED
GENERAL INFORMATION
ABSTRACTS
Accepted abstracts have been published in a supplement to the Annals of
Rheumatic Diseases and can be accessed on the EWRR website: www.ewrr.org
CASH MACHINE
A cash machine is available at the Casino situated below the hotel Marriott.
CERTIFICATE OF ATTENDANCE
A certificate of attendance will be sent by email (to the email address provided
during the registration process) to all duly registered participants, after the
meeting.
FOOD AND BEVERAGE
Complimentary coffee and tea is served in the Place Haute during official coffee
breaks. Lunch is provided in the Place Haute on Friday.
INTERNET
Wireless internet access named «EWRR2019» is available to all participants in the
meeting areas.
LANGUAGE
The official conference language is English. No simultaneous interpretation will
be provided.
MEETING DOCUMENTS AND BADGES
Meeting documents should be collected onsite at the registration desk located at
the Congress Center of Lyon at the Rhône Pasteur Level 1. Name badges must be
worn visibly at all times during the meeting.
MOBILE DEVICES
As a courtesy to all conference attendees and speakers, cellular phones, pagers
and other electronic devices must be operated in silent or vibration mode during
sessions. No cellular phone conversations are permitted during sessions.
NETWORKING EVENTS
Thursday 28 February 2019 | 19:30 Boat Hermès II
Welcome & Networking
Friday 1 March 2019 | 19:30 Hôtel de Ville de Lyon
Official meeting dinner
8
POSTERS & GUIDED POSTER TOURS
All posters will be displayed from Thursday to Saturday.
Mantling Date: Thursday 28 February 2019 | from 10:00
Dismantling Date: Saturday 2 March 2019 | from 10:30
Dismantling Deadline: Saturday 2 March 2019 | 14:00
Posters are located in Salon Pasteur Level 1. Authors of accepted posters are
requested to be at their poster during the assigned poster tour in order to enable
discussion.
Guided poster tour - Thurday 28 February 2019 - 18:00 - 19:30
Adhesive stickers and hanging materials are available at the registration desk
located in the Place Haute.
REGISTRATION DESK OPENING-HOURS
Thursday 28 February 2019 09:30 - 19:00
Friday 1 March 2019 08:00 - 17:30
Saturday 2 March 2019 08:00 - 13:00
SMOKING POLICY
The meeting venue is entirely non-smoking.
SPEAKERS PREVIEW ROOM
The Speakers Preview Room is located in Room Rhône 5 on the workshop level
Rhône Pasteur and is open at the following hours:
Thursday 28 February 2019 11:00 - 19:00
Friday 1 March 2019 08:00 - 17:30
Saturday 2 March 2019 08:00 - 13:00
All speakers are requested to upload their presentation at least 2 hours before
their session, or the day before for the early morning sessions.
SURVEY / MEETING EVALUATION
We would be grateful if you could take a few minutes to answer an online survey
that will be sent to you shortly after the meeting. Your valuable feedback will help
to improve the organisation and quality of future EWRR meetings.
TRAVEL INSURANCE
It is recommended that participants obtain adequate cover for travel, health and
accident insurance before they depart from their countries. EWRR and MCI as
organisers cannot accept responsibility for personal injuries, or loss of, or damage
to, private property belonging to the workshop participants.
9
PROGRAMME OVERVIEW
THURSDAY 28 FEBRUARY 2019
TIME PROGRAMME
10:00 - 12:30 Study groups Rhône 2, 3A, 3B
13:00 - 13:30 Welcome coffee Place Haute
13:30 - 13:40 Welcome & Opening remarks Auditorium Pasteur
13:45 - 15:15 Autoimmunity Auditorium Pasteur
Costantino Pitzalis (UK)
15:15 - 15:45 Coffee break Place Haute
15:45 - 17:15 Systemic effects of inflammation Auditorium Pasteur
Laurence Vico (FR) & Maurizio Cutolo (IT)
17:15 - 18:00 Invited lectures Auditorium Pasteur
Georg Schett (DE) & Charles Dinarello (NL/US)
18:00 - 19:30 Poster tours & discussion Salon Pasteur
19:30 Networking event Boat Hermès II
10PROGRAMME
FRIDAY OVERVIEW
1 MARCH 2019
FRIDAY 1 MARCH 2019
TIME PROGRAMME
08:30 - 10:00 Cell signalling and gene regulation Auditorium Pasteur
Andreas Radbruch (DE)
10:00 - 10:30 Coffee break Place Haute
10:30 - 12:00 IL-17 and IL-17 producing cells Auditorium Pasteur
Anne Puel (FR) & Marije Koenders (NL)
12:00 - 13:30 Lunch break & Meet the experts discussion Place Haute
13:30 - 15:00 Mesenchymal cells Auditorium Pasteur
Chris Buckley (UK)
15:00 - 15:30 Coffee break Place Haute
15:30 - 17:00 Cell-cell interactions Auditorium Pasteur
Ursula Fearon (IR) & Elodie Segura (FR)
17:00 - 17:30 Invited lecture Auditorium Pasteur
Vijay Kuchroo (US)
19:30 Official meeting dinner Hôtel de Ville de Lyon
SATURDAY 2 MARCH 2019
TIME PROGRAMME
08:30 - 10:00 Genes and environment Auditorium Pasteur
Francesco Ciccia (IT)
10:00 - 10:30 Coffee break Place Haute
10:30 - 12:00 Novel therapies Auditorium Pasteur
Cem Gabay (CH) & Christian Jorgensen (FR)
12:00 - 13:00 Invited closing lectures Auditorium Pasteur
Luke o’Neill (IR) & Paul Emery (UK)
13:00 - 13:30 Awards & Closing remarks Auditorium Pasteur
Leuven 2020
13:30 Farewell Place Haute
11PROGRAMME - THURSDAY 28 FEBRUARY 2019
10:00 - 12:30 STUDY GROUPS
10:00 - 12:00 EULAR autoantibody study group Rhône 3A
10:00 - 12:00 EULAR synovitis study group Rhône 3B
10:00 - 12:00 Gene & cell therapy study group Rhône 2
13:00 - 13:30 WELCOME COFFEE Place Haute
13:30 - 13:40 WELCOME & OPENING REMARKS Auditorium Pasteur
Pierre Miossec (FR)
13:45 - 15:15 AUTOIMMUNITY Auditorium Pasteur
Chairs: Francesca Barone (UK) & Guy Serre (FR)
13:45 Synovial pathotypes define prognostic and treatment
response endo-phenotypes in rheumatoid arthritis: towards
precision medicine
Costantino Pitzalis (UK)
14:25 O01 Characterization of the anti-centromere antibody
response in systemic sclerosis patients suggests a broad and
active B cell response
Corrie M. Wortel (NL)
14:35 O06 Higher expression of Siglec-7/9 on granulocytes and
monocytes has a protective role in rheumatoid arthritis
Fabian Andes (DE)
14:45 O03 Circulating follicular helper T cells are increased in
systemic sclerosis and promote plasmablast differentiation
through the IL-21 pathway which can be inhibited by ruxolitinib
Laure Ricard (FR)
14:55 O04 Phenotypic heterogeneity of regulatory T cells in
rheumatoid arthritis
Yasamine El Ahmadi (FR)
15:05 O05 Molecular mimicry and autoimmunity: anti-P.gingivalis
antibody response in ACPA-positive rheumatoid arthritis
Natalia Sherina (SE)
12PROGRAMME - THURSDAY 28 FEBRUARY 2019
15:15 - 15:45 COFFEE BREAK Place Haute
15:45 - 17:15 SYSTEMIC EFFECTS OF INFLAMMATION Auditorium Pasteur
Chairs: Lie Dai (CN) & Hubert Marotte (FR)
15:45 Impact of space flight on bone
Laurence Vico (FR)
16:15 Sex hormones and autoimmunity
Maurizio Cutolo (IT)
16:45 O08 Systemic inflammation originating from the skin or the
intestine combined with biomechanical stress has different
effects on the joints in an in vivo mouse model
Giulua R. Gulino (BE)
16:55 O07 Pathological inflammation in experimental
spondyloarthritis is characterized by high endothelial venules
and ectopic lymphoid structures in the bone marrow
Merlijn H. Kaaij (NL)
17:05 O02 Distinct macrophage phenotype and bioenergetic profiles
in rheumatoid arthritis
Megan M. Hanlon (IR)
17:15 - 18:00 INVITED LECTURES Auditorium Pasteur
17:15 Intestinal metabolites in the control of bone mass and arthritis
Georg Schett (DE)
17:35 40 years of research on cytokines
Charles Dinarello (NL/US)
18:00 - 19:30 POSTER TOURS & DISCUSSION Salon Pasteur
19:30 NETWORKING EVENT Boat Hermès II
13PROGRAMME - FRIDAY 1 MARCH 2019
08:30 - 10:00 CELL SIGNALLING AND GENE REGULATION Auditorium Pasteur
Chairs: Marije Koenders (NL) & Georg Schett (DE)
08:30 TWIST1 controls persistence of the CD4 T cells driving chronic
inflammation
Andreas Radbruch (DE)
09:00 O09 MIR-221-3P is upregulated in rheumatoid arthritis and
affects JAK3/STAT3 signalling in M2-macrophages
Lilian Quero (CH)
09:30 O10 Investigating gene expression patterns and function of
tolerogenic dendritic cells
Lilian Nwosu (UK)
09:40 O11 Inhibition of arginase-1 expression by the transcription
factor FRA-1 in macrophages exacerbates rheumatoid arthritis
inflammation
Nicole Hannemann (DE)
09:50 O12 Sialic acids negatively affect the bone resorptive
capacity of osteoclasts
Anoushka K. Molhoek (NL)
11:30 O13 RNA sequencing detection of gene dysregulation in
B cells sorted from salivary gland tissue and from peripheral
blood reveals new pathways involved in primary Sjögren’s
Elodie Rivière (FR)
10:00 - 10:30 COFFEE BREAK Place Haute
10:30 - 12:00 IL-17 AND IL-17 PRODUCING CELLS Auditorium Pasteur
Chairs: Melissa Noack (FR) & Zoltan Szekanecz (HU)
10:30 Genetic defects of the IL-17 and Th17 pathway
Anne Puel (FR)
11:00 Th17 / T reg defects in chronic inflammation
Marije Koenders (NL)
14PROGRAMME - FRIDAY 1 MARCH 2019
11:30 O14 Interleukin-17 is produced by CD4+ but not CD8+ T cells
after TCR activation in synovial fluid of psoriatic arthritis patients
Xiaofei Xu (NL)
11:40 O15 Synovial derived Th17-lymphocytes from patients
with juvenile idiopathic arthritis induce cartilage degradation
by synovial fibroblasts mediated by MMP9 in an experimental
animal model
Teresa Giani (IT)
11:50 O16 IL-36 signalling in Keratinocytes is mandatory in
imiquimod-induced psoriasis in mice
Jeremie Goldstein (CH)
12:00 - 13:30 LUNCH BREAK & MEET THE EXPERTS Place Haute
With small group discussions on career options for young scientists.
13:30 - 15:00 MESENCHYMAL CELLS Auditorium Pasteur
Chairs: Florence Apparailly (FR) & Cem Gabay (CH)
13:30 Synoviocyte heterogeneity
Chris Buckley (UK)
14:10 O17 Human lymph node stromal cells express self-antigens
targeted by anti-citrullinated protein antibodies: role for tolerance
induction in rheumathoid arthritis
Cristoforo Grasso (NL)
14:20 O18 Epigenetic changes by inhibition of DOT1L affect Wnt
signalling, proliferation and cell cycle in dermal fibroblasts, with
no overall effect on collagen deposition in models of fibrosis
Nathalie Berghen (BE)
14:30 O19 Immunomodulatory activity of adipose-derived
mesenchymal stem cells of ankylosing spondylitis patients
Ewa Kuca-Warnawin (PL)
14:40 O20 LASP1 regulates cell-to-cell contact formations of
fibroblast-like synoviocytes in RA
Denise Beckmann (DE)
15PROGRAMME - FRIDAY 1 MARCH 2019
14:50 O21 MiR-146a an important key player in bone metabolism
Victoria Saferding (AU)
15:00 - 15:30 COFFEE BREAK Place Haute
15:30 - 17:00 CELL-CELL INTERACTIONS Auditorium Pasteur
Chairs: Helen McGettrick (UK) & Frédéric Coutant (FR)
15:30 Hypoxia, angiogenesis and cell metabolism
Ursula Fearon (IR)
16:00 Inflammatory dendritic cells
Elodie Segura (FR)
16:30 O22 Transcriptomics unveils unique biological profile of
tertiary lymphoid structures germinal centers
Serena Colafrancesco (IT)
16:40 O23 Novel subclass of non-classical monocytes are critical for
inflammation
Anna B. Montgomery (US)
16:50 O24 Sclerostin deficiency affects RANKL-mediated osteoclast
differentiation
Johanna Intemann (DE)
17:00 - 17:30 INVITED LECTURE Auditorium Pasteur
17:00 Heterogeneity of Th17 cells
Vijay Kuchroo (US)
19:30 OFFICIAL MEETING DINNER Hôtel de Ville de Lyon
16PROGRAMME - SATURDAY 2 MARCH 2019
08:30 - 10:00 GENES AND ENVIRONMENT Auditorium Pasteur
Chairs: Frédérique Ponchel (UK) & Christian Jorgensen (FR)
08:30 Gut inflammation and arthritis
Francesco Ciccia (IT)
09:10 O25 DNA methylation in lymphocyte subsets as a mediator of
genetic risk in early rheumatoid arthritis
Alex D. Clark (UK)
09:20 O26 Difference between palindromic rheumatism and early
rheumatoid arthritis at the level of gene expression
Shoaib Ajaib (UK)
09:30 O27 Osteocyte-derived podoplanin is an important regulator
of bone remodelling in the K/BxN serum transfer model of
rheumatoid arthritis
Corinna Wehmeyer (UK)
09:40 O28 Fatty acid oxidation can drive human monocyte derived
CCL20 in the RA synovial environment
Lewis C. Rodgers (SE)
09:50 O29 MTOR blockade by rapamycin decreases arthritis and
spondylitis development and severity in HLA-B27 transgenic rats
Sijia Chen (US)
10:00 - 10:30 COFFEE BREAK Place Haute
10:30 - 12:00 NOVEL THERAPIES Auditorium Pasteur
Chairs: Ursula Fearon (IR) & Gyorgy Nagy (HU)
10:30 IL-18/IL-18BP Balance in Systemic Inflammation
Cem Gabay (CH)
11:00 Mesenchymal cells for arthritis treatment
Christian Jorgensen (FR)
11:30 O30 OLT1177™, an oral NLRP3 inflammasome inhibitor,
inhibits acute joint inflammation and circulating IL-1 during gout
flares in humans
Viola Klück (NL)
17PROGRAMME - SATURDAY 2 MARCH 2019
11:40 O31 CD38-expressing memory T cells are expanded in
peripheral blood, contained in inflamed tissue and represent a
potential treatment target in systemic lupus erythematosus
Lennard Ostendorf (DE)
11:50 O32 Selective expansion of a thymic-derived and functionally
competent regulatory T cell population by low-dose IL-2 therapy
in patients with refractory SLE
Jens Y. Humrich (DE)
12:00 - 13:00 INVITED CLOSING LECTURES Auditorium Pasteur
12:00 Krebs cycle in innate Immunity and inflammation
Luke O’Neill (IR)
12:30 If I were 25 today, what field of arthritis research should I select?
Paul Emery (UK)
13:00 - 13:30 AWARDS & CLOSING REMARKS Auditorium Pasteur
Poster awards with the kind support of EULAR
Leuven 2020
13:30 FAREWELL Place Haute
18POSTERS
THURSDAY 28 FEBRUARY 2019
18:00 - 19:30 POSTER TOURS Salon Pasteur
AUTOIMMUNITY 1
Chair: Florence Apparailly (FR)
P001 DIFFERENTIAL EXPRESSION OF KEY METABOLIC GENES IN ANTIGEN-SPECIFIC B CELL
SUBSETS IN RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS /
L. Abreu* - F. Kucher - V. Eckstein - H.-M. Lorenz - R. A. Carvalho - M. Souto-Carneiro
P002 DIFFERENCE BETWEEN PALINDROMIC RHEUMATISM AND EARLY RHEUMATOID
ARTHRITIS AT THE LEVEL OF GENE EXPRESSION / S. Ajaib* - A. Chapman - A. Burska -
K. Mankia - P. Emery - F. Ponchel
P006 INVESTIGATION OF IGA IMMUNE COMPLEX CAPTURE BY FCRL4+ B CELLS IN PERIPHERAL
BLOOD AND SYNOVIAL FLUID / J. Cameron* - E. Clay - A. Filer - G. Vidal-Pedrola - A. Anderson
- J. Isaacs - K. Raza - D. Scheel-Toellner
P007 AUTOANTIBODIES’ TITRE CHANGES DURING ANTI-BLYS TREATMENT IN SYSTEMIC LUPUS
ERYTHEMATOSUS / I. Cavazzana* - C. Pozzari - R. Kumar - R. Ottaviani - M. Fredi - S. Piantoni
- A. Tincani - F. Franceschini
P008 INFLUENCE OF M-CSF POLARISATION OF MONOCYTES AND ACTIVATION OF THE M-CSF
MACROPHAGES BY PRO-INFLAMMATORY OR OTHER POLARISING CYTOKINES, ON
EXPRESSION OF PEPTIDYLARGININE DEIMINASES 2 AND 4 / M.-C. Méchin - G. Serre -
C. Clavel*
P009 TRANSCRIPTOMICS UNVEILS UNIQUE BIOLOGICAL PROFILE OF TERTIARY LYMPHOID
STRUCTURES GERMINAL CENTERS / S. Colafrancesco* - E. Pipi - J. Campos - S. Nayar -
V. Iannizzotto - R. Priori - G. Valesini - B. Fisher - F. Barone
P010 CHARACTERIZATION OF DISTINCT DENDRITIC CELL SUBSETS IN THE CONTEXT OF
CHRONIC INFLAMMATION / F. Coutant* - J. Zhang - P. Miossec
P011 THE ROLE OF CELLULAR METABOLISM IN RHEUMATOID AND PSORIATIC ARTHRITIS /
C. C. Cunningham* - S. Ansboro - T. McGarry - D. J. Veale - U. Fearon
AUTOIMMUNITY 2
Chair: Gunter Steiner (AU)
P012 PATIENTS WITH CANCER AND PREEXISTING AUTOIMMUNE AND INFLAMMATORY
DISEASES TREATED BY ANTI-PROGRAMMED DEATH 1 (PD-1) ANTIBODIES AT GUSTAVE
ROUSSY CANCER CENTER / F.-X. Danlos* - M. Najean - A.-L. Voisin - A. Marabelle - M. Texier
- O. Lambotte
19POSTERS
THURSDAY 28 FEBRUARY 2019
18:00 - 19:30 POSTER TOURS Salon Pasteur
P013 BARICITINIB-ASSOCIATED CHANGES IN TYPE I IFN GENE SIGNATURE DURING A 24-WEEK
PHASE 2 CLINICAL SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) TRIAL / T. Dörner - Y. Tanaka
- M. Petri - J. S. Smolen - E. R. Dow - R. E. Higgs - R. J. Benschop - A. Abel - M. E. Silk - S. de
Bono - R. W. Hoffman - F. Durand (Presenter only)*
P014 PHENOTYPIC HETEROGENEITY OF REGULATORY T CELLS IN RHEUMATOID ARTHRITIS /
Y. El Ahmadi* - M. Cren - Y.-M. Pers - E. Dufourq-Lopez - C. Jorgensen - R. Fereirra -
P. Louis-Plence
P015 AUTOANTIBODY PROFILING FOR RESPONSE TO BARICITINIB IN PATIENTS WITH
RHEUMATOID ARTHRITIS AND NO OR LIMITED EXPOSURE TO METHOTREXATE /
L. Martinez Gamboa - H. Bang - M. Issa - S. Zuckerman - A. Cardoso - T. Holzkaemper -
I. de la Torre - Y. Tanaka - E. Feist*
P016 VASCULAR INVOLVEMENT IN RHEUMATIC DISEASES - THE ROLE OF IMAGING AND
IMMUNOLOGICAL BIOMARKERS / K. M. Fischer* - H. Przepiera-Będzak - I. Brzosko -
M. Sawicki - M. Brzosko
P017 NON-ANTIBODY MEDIATED PATHOGENIC ROLES FOR SYNOVIAL B CELLS IN ACPA+ AND
ACPA- RHEUMATOID ARTHRITIS. / A. Floudas* - C. Low - M. Biniecka - D. J. Veale - U. Fearon
P018 ANTI-CARBAMYLATED PROTEIN ANTIBODIES AS A CLINICAL RESPONSE PREDICTOR IN
RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ABATACEPT / M. Fredi* - M. Boldini
- R. Kumar - S. Piantoni - I. Cavazzana - E. Garrafa - C. Bazzani - A. Tincani - F. Franceschini
P019 IS TREATMENT RESPONSE INFLUENCED BY BODY MASS INDEX IN JUVENILE IDIOPATHIC
ARTHRITIS? / T. Giani* - R. Cimaz
P021 DIFFERENTIAL ACPA BINDING TO NUCLEAR ANTIGENS REVEALS A DISTINCT SUBSET OF
ACETYLATION CROSS-REACTIVE AUTOANTIBODIES IN RHEUMATOID ARTHRITIS /
G. Wigerblad - K. A. Lloyd - P. Sahlström - E. Ossipova - K. Chemin - J. Steen - P. J. Titcombe
- D. Zhou - R. Stålesen - J. Rönnelid - D. L. Mueller - M. J. Kaplan - K. Skriner - L. Klareskog -
F. Wermeling - V. Malmström - C. Grönwall*
P022 DISTINCT MACROPHAGE PHENOTYPE AND BIOENERGETIC PROFILES IN RHEUMATOID
ARTHRITIS / M. M. Hanlon* - T. McGarry - M. Canavan - C. Low - D. J. Veale - U. Fearon
P023 TENOSYNOVITIS AND HLA-SE PREDICT ARTHRITIS ONSET IN ACPA-POSITIVE INDIVIDUALS
AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS. / A. H. Hensvold* - Y. Kisten -
M. Hansson - A. Cîrciumaru - M. Sun - G. Fei - E. af Klint - H. Rezaei - A. Antovic - A. I. Catrina
20POSTERS
THURSDAY 28 FEBRUARY 2019
18:00 - 19:30 POSTER TOURS Salon Pasteur
AUTOIMMUNITY 3
Chair: Costantino Pitzalis (UK)
P024 DISTURBED SEXUAL FUNCTIONING IN FEMALE PATIENTS WITH IDIOPATHIC
INFLAMMATORY MYOPATHIES / B. Hermankova* - M. Spiritovic - H. Smucrova - S. Oreska -
H. Storkanova - K. Pavelka - L. Senolt - H. Mann - J. Vencovsky - M. Tomcik
P025 DISTURBED SEXUAL FUNCTIONING IN FEMALE PATIENTS WITH SYSTEMIC SCLEROSIS /
B. Hermankova* - M. Spiritovic - H. Smucrova - S. Oreska - H. Storkanova - K. Pavelka -
J. Vencovsky - L. Senolt - R. Becvar - M. Tomcik
P026 CONTROL OF A2,6-SIALYLATION IN B-CELLS, AND CONSEQUENCES OF REDUCED B-CELL
SIALYLATION IN PATIENTS WITH RHEUMATOID ARTHRITIS. / L. Johnston* - L. Ouboussad -
A. Aslam - M. H. Buch
P027 SRC-LIKE ADAPTOR PROTEIN EXPRESSION IN RHEUMATOID ARTHRITIS / P. Királyhidi* -
E. S. Molnár - E. J. Baricza - N. Marton - E. Buzás - G. Nagy
P030 TRANSCRIPTIONAL LANDSCAPES OF MEMORY T CELLS FROM PATIENTS WITH JUVENILE
IDIOPATHIC ARTHRITIS / P. Maschmeyer - G. A. Heinz - F. Heinrich - P. Durek - L. E. Wirth -
S. L. von Stuckrad - K. Lehmann - C. L. Tran - B. Orak - H.-D. Chang - T. Kallinich - A. Radbruch
- M.-F. Mashreghi*
P031 SIALIC ACIDS NEGATIVELY AFFECT THE BONE RESORPTIVE CAPACITY OF OSTEOCLASTS /
A. K. Molhoek* - R. E. Li - I. D. Jansen - T. Schoenmaker - T. J. de Vries - S. J. van Vliet -
Y. van Kooyk
P032 SIALIC ACIDS INHIBIT NEUTROPHIL EXTRACELLULAR TRAP FORMATION / A. K. Molhoek*
- M. M. van Gool - R. E. Li - M. van Egmond - S. J. van Vliet - Y. van Kooyk
P033 CD38-EXPRESSING MEMORY T CELLS ARE EXPANDED IN PERIPHERAL BLOOD,
CONTAINED IN INFLAMED TISSUE AND REPRESENT A POTENTIAL TREATMENT TARGET
IN SYSTEMIC LUPUS ERYTHEMATOSUS / L. Ostendorf* - P. Enghard - F. Hiepe - T. Alexander
P034 PRESENCE OF A SPECIFIC DEFECT IN M2 POLARIZATION OF BLOOD MONOCYTES FROM
PATIENTS WITH RHEUMATOID ARTHRITIS, ASSOCIATED WITH INCREASED MICRORNA-155
/ A. Paoletti* - J. Rohmer - B. Ly - J. Pascaud - E. Riviere - G. Nocturne - X. Mariette
AUTOIMMUNITY 4
Chair: Maurizio Cutulo (IT)
P035 OCCUPATIONAL PHYSICAL WORKLOAD AND DEVELOPMENT OF ANTI-COLLAGEN
TYPE II ANTIBODIES IN RHEUMATOID ARTHRITIS: RESULTS FROM THE SWEDISH EIRA
POPULATION-BASED CASE-CONTROL STUDY / E. Pertsinidou* - P. Zeng - B. Brynedal -
V. A. Manivel - L. Klareskog - M. Mullazehi - S. Saevarsdottir - C. Bengtsson - L. Alfredsson -
J. Rönnelid
21POSTERS
THURSDAY 28 FEBRUARY 2019
18:00 - 19:30 POSTER TOURS Salon Pasteur
P036 B CELL NUMBER REDUCTION HAS A PREDICTIVE VALUE FOR RESPONSE TO BELIMUMAB
IN A COHORT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / S. Piantoni -
L. Andreoli - T. Lowin - R. Kumar - F. Regola - P. Airò - I. Cavazzana* - F. Franceschini - A. Tincani
- G. Pongratz
P037 ANTI-CARBAMYLATED PROTEIN ANTIBODIES: ARE THEY USEFUL FOR THE DIAGNOSIS OF
RHEUMATOID ARTHRITIS? / F. Ponchel* - L. Hunt - M. van Delft - P. Emery - L. Trouw
P038 IN VIVO DEMONSTRATION OF TMTNF REVERSE SIGNALING: SIGNIFICANCE IN THE
THERAPEUTIC RESPONSE TO ANTI-TNF AGENTS DURING MURINE ARTHRITIS / B. Rauwel*
- N. Simons - K. Diallo - M. Baron - Y. Degboe - A. Kruglov - S. Nedospasov - A. Constantin -
A. Cantagrel - J.-L. Davignon
P039 CIRCULATING FOLLICULAR HELPER T CELLS ARE INCREASED IN SYSTEMIC SCLEROSIS
AND PROMOTE PLASMABLAST DIFFERENTIATION THROUGH THE IL-21 PATHWAY WHICH
CAN BE INHIBITED BY RUXOLITINIB / L. Ricard* - V. Jachiet - F. Malard - Y. Ye - N. Stocker -
S. Rivière - P. Senet - J.-B. Monfort - O. Fain - M. Mohty - B. Gaugler - A. Mekinian
P040 THE EUROPEAN CONSENSUS FINDING STUDY GROUP ON AUTOANTIBODIES 2017/18
INVESTIGATION. CHARACTERISATION OF AUTOANTIBODY CONTENT IN A NEW
INTERNATIONAL REFERENCE STANDARD FOR DENSE FINE SPECKLED 70KD (DFS70)
AUTOANTIBODIES / J. Rönnelid* - M. Blüthner - C. Dahle - L. Andrade - E. Feist - D. Hamann
on behalf of The European Consensus Finding Study Group on autoantibodies (ECFSG)*
P041 IMMUNOLOGICAL CHARACTERISTICS AND DISTRIBUTION OF CRYOGLOBULINS IN A
COHORT OF 13000 PATIENTS OVER 6 YEARS. / M. N. Sarda* - P. Miossec
P042 MOLECULAR MIMICRY AND AUTOIMMUNITY: ANTI-P.GINGIVALIS ANTIBODY RESPONSE
IN ACPA-POSITIVE RHEUMATOID ARTHRITIS / N. Sherina* - N. Sippl - L. Israelsson -
E. Le Maitre - N. Kharlamova - M. Hansson - K. Eriksson - T. Yucel-Lindberg - V. Malmström -
K. Amara - K. Lundberg
P043 INFECTION WITH CITRULLINATING PORPHYROMONAS GINGIVALIS CAN INDUCE
AUTOIMMUNITY TO HUMAN RIBOSOMAL PROTEINS / M. Jenning - B. Marklein - Z. Konthur
- U. Nonhoff - G.-R. Burmester - K. Skriner*
AUTOIMMUNITY 5
Chair: Sander Tas (NL)
P044 EFFECT OF SPECIALIZED 6-MONTH ADL TRAINING WITH SUBSEQUENT A 6-MONTH
FOLLOW-UP PERIOD IN PATIENTS WITH MYOSITIS - PRELIMINARY DATA / M. Spiritovic* -
S. Oreska - H. Storkanova - B. Hermankova - P. Cesak - A. Rathouska - K. Kubinova - M. Klein
- L. Vernerova - O. Ruzickova - H. Mann - K. Pavelka - L. Senolt - J. Vencovsky - M. Tomcik
22POSTERS
THURSDAY 28 FEBRUARY 2019
18:00 - 19:30 POSTER TOURS Salon Pasteur
P045 EFFECT OF SPECIALIZED 6-MONTH PHYSICAL-OCCUPATIONAL INTERVENTION WITH
SUBSEQUENT 6-MONTH FOLLOW-UP PERIOD IN PATIENTS WITH SCLERODERMA -
PRELIMINARY DATA / M. Spiritovic* - H. Smucrova - S. Oreska - H. Storkanova - B. Hermankova
- P. Cesak - A. Rathouska - O. Ruzickova - K. Pavelka - L. Senolt - J. Vencovsky - R. Becvar -
M. Tomcik
P046 NECROSTATIN-1 AMELIORATES NEUTROPHILIC ASTHMA BY INHIBITING NEUTROPHIL
RELEASE NETS / X. Han - H. Jie - J. Wang - J. Zhang - J. He - C. Yu - E. Sun*
P047 THE PLASMA CELL BONE MARROW NICHE IN ACPA+ RA PATIENTS CONTAIN CITRULLINE
SPECIFIC CELLS / R. Thyagarajan* - A. H. Hensvold - L. Israelsson - J. Steen - H. Wähämaa -
A. van Vollenhoven - K. Amara - A. I. Catrina - V. Malmström - C. Grönwall
P048 PREDICTIVE VALUE OF THE DIFFERENT CAPILLAROSCOPIC PATTERNS IN EARLY RAYNAUD
PHENOMENON / J. Uceda* - R. Hernandez - J. L. Marenco
P049 AGE-ASSOCIATED B CELLS IN EARLY DRUG-NAÏVE RHEUMATOID ARTHRITIS PATIENTS /
G. Vidal Pedrola* - A. Pratt - A. Mellor - D. Scheel-Toellner - J. Isaacs - A. Anderson
P050 JAN GÖSTA WALDENSTRÖM AND RHEUMATOLOGY / F. Wollheim*
P051 CHARACTERIZATION OF THE ANTI-CENTROMERE ANTIBODY RESPONSE IN SYSTEMIC
SCLEROSIS PATIENTS SUGGESTS A BROAD AND ACTIVE B CELL RESPONSE / C. M. Wortel*
- N. M. van Leeuwen - M. Boonstra - J. A. Bakker - R. E. Toes - T. W. Huizinga -
J. K. de Vries-Bouwstra - H. U. Scherer
P052 AUTO-ANTIBODIES AGAINST POST TRANSLATIONAL MODIFIED PROTEINS IN
OSTEOARTHRITIS: PILOT DATA COMPARING SYNOVIAL FLUID AND SERA / X. Xie* -
M. V. Delft - L. Trouw - P. Conaghan - F. Ponchel
CELL SIGNALLING AND GENE REGULATION 1
Chair: Ursula Fearon (IR)
P053 LNCRNA HOTAIR PROMOTES PROLIFERATION AND INVASION OF FIBROBLAST-LIKE
SYNOVIOCYTES AS MICRORNA SPONGING IN RA PATIENTS. / X. Bi - Y. F. Pan* - X. Q. Luo -
M. L. Wang - Y. X. Chen
P054 IRF-1 IS CRITICAL FOR THE TNF-DRIVEN INTERFERON RESPONSE IN RHEUMATOID
FIBROBLAST-LIKE SYNOVIOCYTES / M. Bonelli* - K. Dalwigk - A. Platzer - I. Calvo - S. Hayer
- B. Niederreiter - J. Holinka - F. Sevelda - T. Pap - G. Steiner - G. Superti-Furga - J. Smolen -
H. Kiener - T. Karonitsch
P055 CXCL13 AS BIOMARKER FOR HISTOLOGICAL INVOLVEMENT IN SJOGREN’S SYNDROME /
S. Colafrancesco* - R. Priori - C. Smith - A. Minniti - V. Iannizzotto - E. Pipi - S. Nayar -
J. Campos - D. Lucchesi - F. Arienzo - B. Cerbelli - C. Giordano - G. Valesini - M. Bombardieri
- B. A. Fisher - F. Barone
23POSTERS
THURSDAY 28 FEBRUARY 2019
18:00 - 19:30 POSTER TOURS Salon Pasteur
P056 A NOVEL PGC-1B/NFATC-1 PATHWAY IN MONOCYTES FACILITATES OSTEOCLASTOGENESIS
IN RHEUMATOID ARTHRITIS / J.-D. Ma - J. Jing - Y.-Q. Mo - Q.-H. Li - J.-Z. Lin - L.-F. Chen -
L. Dai*
P057 ARTEMETHER SUPPRESSES MIGRATION AND INVASION OF FIBROBLAST-LIKE
SYNOVIOCYTES THROUGH INHIBITION OF THE RHO SIGNALING PATHWAY IN RHEUMATOID
ARTHRITIS / J. Jing - J.-W. Wang - J.-D. Ma - L.-F. Chen - L. Dai*
P058 CHEMOKINE CCL18 ENRICHED IN SYNOVIAL FLUID IS INVOLVED IN JOINT DESTRUCTION
THROUGH PROMOTING MIGRATION OF FIBROBLAST-LIKE SYNOVIOCYTES IN RHEUMATOID
ARTHRITIS / Y.-Q. Mo - G.-C. Zhang - J. Jing - J.-D. Ma - L. Dai*
P059 DISSECTING THE ROLE OF GREMLIN 1 IN SYSTEMIC SCLEROSIS / L. Duffy* - S. O’Reilly
P062 HISTONE DEACETYLASE 1 (HDAC1): A NOVEL THERAPEUTIC TARGET IN RHEUMATOID
ARTHRITIS / L. Goschl - V. Saferding - M. Kugler - J. Backlund - P. Mathias - C. Scheinecker - W.
Ellmeier - S. Günter - M. Bonelli*
P063 INHIBITION OF ARGINASE-1 EXPRESSION BY THE TRANSCRIPTION FACTOR FRA-1 IN
MACROPHAGES EXACERBATES RHEUMATOID ARTHRITIS INFLAMMATION /
N. Hannemann* - S. Cao - A. Schnelzer - J. Jordan - M. Eberhardt - U. Schleicher - S. Uebe -
A. Ekici - J. Rech - T. Bäuerle - C. Bogdan - J. Vera - G. Schett - A. Bozec
P065 REGULATION OF JOINT DESTRUCTION BY ACTIVIN A IN RHEUMATOID ARTHRITIS /
V. Kracke* - M. Fennen - J. Intemann - E. Werbenko - D. de Gorter - P. Paruzel - T. Pap -
B. Dankbar
P066 MIR-342-3P PROMOTES CELL SURVIVAL AND MOTILITY OF OSTEOCLAST PRECURSORS /
C. Lozano* - V. Estibals - I. Duroux-Richard - F. Apparailly
CELL SIGNALLING AND GENE REGULATION 2
Chair: Marije Koenders (NL)
P067 TOFACITINIB IMPAIRS MONOCYTE-DERIVED DENDRITIC CELL DIFFERENTIATION IN
RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS / V. Marzaioli* - M. Canavan -
A. Floudas - S. Wade - C. Low - D. J. Veale - U. Fearon
P068 RHEUMATOID ARTHRITIS PERIPHERAL CD14+ MONOCYTES ARE HYPER-INFLAMMATORY,
HYPER-GLYCOLYTIC AND RETAIN A MEMORY BIAS TOWARD M1 MACROPHAGES /
T. Mcgarry* - M. Hanlon - U. Fearon - D. J. Veale
P069 CONSTITUTIVE OVEREXPRESSION OF INTERLEUKIN 38 HAS A NEGATIVE IMPACT ON
HUMAN NHK KERATINOCYTE FITNESS / L. Mermoud* - D. Talabot-Ayer - N. Brembilla -
J. Julia Borowczyk-Michalowska - G. Palmer
24POSTERS
THURSDAY 28 FEBRUARY 2019
18:00 - 19:30 POSTER TOURS Salon Pasteur
P070 MIR-221-3P IS UPREGULATED IN RHEUMATOID ARTHRITIS AND AFFECTS JAK3/STAT3
SIGNALLING IN M2-MACROPHAGES / L. Quero* - E. Hanser - A. N. Tiaden - D. Kyburz
P071 RNA SEQUENCING DETECTION OF GENE DYSREGULATION IN B CELLS SORTED FROM
SALIVARY GLAND TISSUE AND FROM PERIPHERAL BLOOD REVEALS NEW PATHWAYS
INVOLVED IN PRIMARY SJÖGREN’S SYNDROME PATHOPHYSIOLOGY / E. Rivière* -
N. Tchitchek - G. Nocturne - J. Pascaud - S. Boudaoud - A. Thai - N. Allaire - B. Jagla -
M. Mingueneau - X. Mariette
P072 MEFV/MIR-326 AXIS INVOLVEMENT IN HUMAN MACROPHAGE POLARIZATION / M. Robin*
- G. Sarrabay - B. Peynircioglu - S. Ozen - I. Touitou - I. Duroux-Richard - F. Apparailly
P073 HIGH LDL LEVELS LESSEN BONE DESTRUCTION DURING ANTIGEN-INDUCED ARTHRITIS
BY INHIBITING OSTEOCLAST FORMATION AND FUNCTION / M. H. van den Bosch -
G. Ascone - I. Di Ceglie* - B. Walgreen - A. W. Sloetjes - E. Lindhout - I. Bot - F. A. van de Loo
- M. I. Koenders - P. M. van der Kraan - A. B. Blom - P. L. van Lent
P074 THE ALARMIN S100A9 HAMPERS OSTEOCLAST DIFFERENTIATION FROM CIRCULATING
PRECURSORS BY REDUCING THE EXPRESSION OF RANK / M. H. van den Bosch -
I. Di Ceglie* - A. B. Blom - C. Logie - J. H. Martens - J. Roth - T. Vogl - C. S. Goodyear -
P. M. van der Kraan - P. L. van Lent
P075 TARGETING NF-KB SIGNALLING IN B CELLS: A POTENTIAL NEW TREATMENT MODALITY
FOR ANCA-ASSOCIATED VASCULITIS / J. P. Van Hamburg* - P. Tuijnenburg - B. Helder -
L. S. van Keep - L. A. Rutten - K. Wesenhagen - P. Kucharzewska - M. H. Jansen - A. Al-Soudi
- P. L. Klarenbeek - H. K. Olsson - N. de Vries - T. W. Kuijpers - S. W. Tas
P076 SYNOVIAL TISSUE FROM RHEUMATOID ARTHRITIS PATIENTS SHED THEIR ANTI-
INFLAMMATORY - AND EFFEROCYTOSIS RECEPTOR MER / J. Vullings - C. Waterborg -
M. Koenders - P. van der Kraan - F. van de Loo*
P077 DYSREGULATED MIR-125A PROMOTES JOINT ANGIOGENESIS THROUGH ENHANCED
GLYCOLYSIS / S. M. Wade* - N. Ohnesorge - H. McLaouglin - M. Biniecka - T. McGarry -
M. Canavan - D. J. Veale - B. Kennedy - U. Fearon
P078 TRANSFORMING GROWTH FACTOR-BETA DAMPENS PRO-INFLAMMATORY INTERLEUKIN-6
SIGNALING IN CHONDROCYTES BY DECREASING THE INTERLEUKIN-6 RECEPTOR /
R. Wiegertjes* - A. van Caam - H. van Beuningen - P. van der Kraan - F. van de Loo -
E. Blaney Davidson
25POSTERS
THURSDAY 28 FEBRUARY 2019
18:00 - 19:30 POSTER TOURS Salon Pasteur
CELL-CELL INTERACTIONS
Chair: Gyorgy Nagy (HU)
P079 IS IGM RHEUMATOID FACTOR PRESENT ON CIRCULATING EXTRACELLULAR VESICLES OF
RHEUMATOID ARTHRITIS PATIENTS A POTENTIAL BIOMARKER FOR DISEASE SEVERITY? /
O. Arntz - B. Pieters - R. Thurlings - P. V. D. Kraan - F. V. D. Loo*
P080 THE EFFECT OF ACTIVIN A AND FOLLISTATIN ON THE INTERACTION OF ENDOTHELIAL
CELLS AND RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS / I. Aykara* - M. Diller -
S. Rehart - U. Müller-Ladner - E. Neumann
P081 LASP1 REGULATES CELL-TO-CELL CONTACT FORMATIONS OF FIBROBLAST-LIKE
SYNOVIOCYTES IN RA / D. Beckmann* - A. Krause - U. Hansen - H. P. Kiener - T. Kamradt -
T. Pap - A. Korb-Pap
P082 SCLEROSTIN DEFICIENCY AFFECTS RANKL-MEDIATED OSTEOCLAST DIFFERENTIATION /
J. Intemann* - C. Wehmeyer - D. J. de Gorter - V. Kracke - P. Paruzel - I. Kramer - M. Kneissel
- T. Pap - B. Dankbar
P083 NOVEL SUBCLASS OF NON-CLASSICAL MONOCYTES ARE CRITICAL FOR INFLAMMATION /
A. B. Montgomery* - P. J. Homan - D. Winter - H. R. Perlman
P084 SALIVARY GLAND EPITHELIAL CELLS FROM SJÖGRENS’ PATIENTS INCREASE B
LYMPHOCYTES SURVIVAL AND ACTIVATION / E. Rivière* - J. Pascaud - A. Virone - B. Ly -
A. Paoletti - J. Rohmer - S. Bitoun - G. Nocturne - X. Mariette
P085 ACTIVATED MEMORY T CELLS PRODUCE LIGANDS THAT CAUSE NF-KB-DEPENDENT
INFLAMMATORY ACTIVATION OF THE ENDOTHELIUM / K. C. Jeucken - J. P. van Hamburg
- S. W. Tas*
CYTOKINES WITH FOCUS ON IL-17 AND IL-17 PRODUCING CELLS 1
Chair: Zoltan Szekanecz (HU)
P086 SYSTEMIC OVEREXPRESSION OF INTERLEUKIN-22 INDUCES EXPRESSION OF THE
NEGATIVE IMMUNE-REGULATOR SOCS3 AND POTENTLY REDUCES COLLAGEN-INDUCED
ARTHRITIS IN MICE / J. Aarts* - D. Roeleveld - B. Walgreen - M. Helsen - E. Vitters -
F. van de Loo - P. van Lent - W. van den Berg - P. van der Kraan - M. Koenders
P087 THE ANTI-INFLAMMATORY CYTOKINE INTERLEUKIN 37 IS AN ENDOGENOUS INHIBITOR
OF TRAINED IMMUNITY / G. Cavalli* - M. Gresnigt - T. Nemkov - R. Arts - A. D’Alessandro -
S. Giugliano - E. Eisenmensser - L. Dagna - L. Joosten - M. Netea - C. Dinarello
P088 CHARACTERIZATION OF NOVEL HUMANIZED IL-17 MOUSE PRECLINICAL PLATFORMS
FOR THE EFFICACY EVALUATION OF ANTI-HUMAN IL17 THERAPEUTICS / E. Christodoulou-
Vafeiadou* - L. Ntari - K. Kranidioti - M. C. Denis - N. Karagianni - G. Kollias
26POSTERS
THURSDAY 28 FEBRUARY 2019
18:00 - 19:30 POSTER TOURS Salon Pasteur
P089 MUCOSAL-ASSOCIATED INVARIANT T (MAIT)-CELL-DERIVED IL-17A AND IL-17F
PRODUCTION IS IL-23-INDEPENDENT AND BIASED TOWARDS IL-17F / S. Cole* -
A. Maroof
P087 THE ANTI-INFLAMMATORY CYTOKINE INTERLEUKIN 37 IS AN ENDOGENOUS INHIBITOR
OF TRAINED IMMUNITY / G. Cavalli* - M. Gresnigt - T. Nemkov - R. Arts - A. D’Alessandro -
S. Giugliano - E. Eisenmensser - L. Dagna - L. Joosten - M. Netea - C. Dinarello
P088 CHARACTERIZATION OF NOVEL HUMANIZED IL-17 MOUSE PRECLINICAL PLATFORMS
FOR THE EFFICACY EVALUATION OF ANTI-HUMAN IL17 THERAPEUTICS / E. Christodoulou-
Vafeiadou* - L. Ntari - K. Kranidioti - M. C. Denis - N. Karagianni - G. Kollias
P089 MUCOSAL-ASSOCIATED INVARIANT T (MAIT)-CELL-DERIVED IL-17A AND IL-17F
PRODUCTION IS IL-23-INDEPENDENT AND BIASED TOWARDS IL-17F /
S. Cole* - A. Maroof
P090 PRO-INFLAMMATORY CYTOKINES AND CELL INTERACTIONS BETWEEN PBMC AND
SYNOVIOCYTES INDUCE RETRACTION AND FORMATION OF PSEUDOPODIA / S. Filali* -
M. Noack - A. Geloen - P. Miossec
P091 EFFECTS OF BIOLOGICS ON IL-17A AND TNF INDUCED CYTOKINE SECRETION ON
SYNOVIAL FIBROBLASTS FROM RHEUMATOID AND PSORIATIC ARTHRITIS PATIENTS /
K. Frommer* - S. Rehart - U. Müller-Ladner - E. Neumann
P092 SYNOVIAL DERIVED TH17-LYMPHOCYTES FROM PATIENTS WITH JUVENILE IDIOPATHIC
ARTHRITIS INDUCE CARTILAGE DEGRADATION BY SYNOVIAL FIBROBLASTS MEDIATED
BY MMP9 IN AN EXPERIMENTAL ANIMAL MODEL / T. Giani* - F. Margheri - M. Del Rosso -
L. Maggi - F. Annunziato - R. Cimaz
P093 IL-36 SIGNALING IN KERATINOCYTES IS MANDATORY IN IMIQUIMOD-INDUCED PSORIASIS
IN MICE / J. Goldstein* - E. Y. Bassoy - J. Palomo - E. Rodriguez - C. Gabay
P094 EFFECTIVENESS AND SECURITY OF SECUKINUMAB IN PATIENTS WITH PSORIASTIC
ARTHRITIS IN REAL CLINICAL PRACTICE / R. Hernández* - J. Uceda - A. Perez Gil -
J. L. Marenco
CYTOKINES WITH FOCUS ON IL-17 AND IL-17 PRODUCING CELLS 2
Chair: Jean-Michel Dayer (CH)
P095 INFLAMMATORY BOWEL DISEASE, DURING ANTI IL 17 TREATMENT / R. Hernández* -
A. Perez Gil - J. Uceda - J. L. Marenco de la Fuente
P096 THE ROLE OF THE IL-23/TH17 AXIS AS MODULATOR OF B CELL-MEDIATED (AUTO)IMMUNE
RESPONSES / R. Pfeifle - J. Kittler* - T. Rothe - G. Schett - G. Krönke
27POSTERS
THURSDAY 28 FEBRUARY 2019
18:00 - 19:30 POSTER TOURS Salon Pasteur
P097 INTRACELLULAR INTERLEUKIN-1 RECEPTOR ANTAGONIST RELEASED UPON CELL DEATH
ACTS AS AN ALARMIN INHIBITOR IN ALDARA CREAM-INDUCED PSORIASIS-LIKE SKIN
INFLAMMATION / P. Martin* - G. Palmer - E. Rodriguez - J. Palomo - C. Gabay
P099 COMPARISON OF IL-17A AND IL-17F EFFECTS ON DIFFERENT CELL TYPES / M. Noack* -
P. Miossec
P100 SYSTEMIC AND LOCAL IL-17A AND MIR-146A LEVELS IN RHEUMATOID ARTHRITIS
PATIENTS / R. Shumnalieva* - D. Kachakova - T. Velikova - S. Monov - R. Kaneva -
Z. Kolarov
P101 SYSTEMIC AND LOCAL IL-17A AND MIR-155 LEVELS IN RHEUMATOID ARTHRITIS PATIENTS /
R. Shumnalieva* - D. Kachakova - T. Velikova - S. Monov - R. Kaneva - Z. Kolarov
P102 HIGH DIMENSIONAL PROFILING OF REGULATORY T CELLS IN SPONDYLOARTHRITIS
REVEALS CELLULAR HETEROGENEITY / D. Simone* - M. H. Al Mossawi - I. Brough - L. Chen
- F. Penkava - A. Ridley - H. Shi - L. Tucker - N. Yager - P. Bowness
P103 INTERLEUKIN-17 IS PRODUCED BY CD4+ BUT NOT CD8+ T CELLS AFTER TCR ACTIVATION
IN SYNOVIAL FLUID OF PSORIATIC ARTHRITIS PATIENTS / X. Xu* - N. Davelaar -
A.-M. Otten-Mus - P. Asmawidjaja - J. Hazes - D. Baeten - M. Vis - R. Bisoendial -
E. Lubberts
GENES & ENVIRONMENT
Chair: Chris Buckley (UK)
P104 ANAEROPLASMA, A POTENTIAL ANTI-INFLAMMATORY PROBIOTIC FOR THE TREATMENT
OF CHRONIC INTESTINAL INFLAMMATION / A. Beller* - A. Kruglov - P. Durek - V. von Goetze
- U. Hoffmann - R. Maier - K. Heiking - B. Siegmund - G. A. Heinz - M.-F. Mashreghi -
A. Radbruch - H.-D. Chang
P105 IDENTIFICATION OF RARE CODING VARIANTS IN IL-1-RELATED PATHWAYS IN PATIENTS
WITH ADULT-ONSET STILL’S DISEASE / G. Cavalli* - R. van Deuren - P. Arts - M. Steehouwer
- P. Sfriso - S. Colafrancesco - R. Priori - L. Cantarini - E. Baldissera - F. van de Veerdonk -
L. Dagna - A. Hoischen - C. A. Dinarello
P106 DNA METHYLATION IN LYMPHOCYTE SUBSETS AS A MEDIATOR OF GENETIC RISK IN
EARLY RHEUMATOID ARTHRITIS / A. D. Clark* - N. Nair - A. J. Skelton - A. E. Anderson -
N. Thalayasingam - N. Naamane - J. Diboll - J. Massey - S. Eyre - A. Barton - J. D. Isaacs -
L. N. Reynard - A. G. Pratt
P107 POLYMORPHISMS IN SLC2A9 AND SLC22A12 GENES ARE RELATED TO HYPERURICEMIA,
GOUT AND ALSO TO HYPOURICEMIA / K. Pavelcova* - J. Bohata - K. Pavelka - B. Stiburkova
28POSTERS
THURSDAY 28 FEBRUARY 2019
18:00 - 19:30 POSTER TOURS Salon Pasteur
P108 FATTY ACID OXIDATION CAN DRIVE HUMAN MONOCYTE DERIVED CCL20 IN THE RA
SYNOVIAL ENVIRONMENT / L. C. Rodgers* - J. Cole - K. Rattigan - M. P. Barrett - N. Kurian -
I. B. McInnes - C. S. Goodyear
P109 EXPRESSION LEVELS OF MIR-21 AND MIR-29 IN THE SERUM OF SYSTEMIC SCLEROSIS
PATIENTS / R. Shumnalieva* - D. Kachakova - V. Shoumnalieva-Ivanova - P. Miteva - R. Kaneva
- Z. Kolarov - S. Monov
MESENCHYMAL CELLS
Chair: Christian Jorgensen (FR)
P110 EPIGENETIC CHANGES BY INHIBITION OF DOT1L AFFECT WNT SIGNALING, PROLIFERATION
AND CELL CYCLE IN DERMAL FIBROBLASTS, WITH NO OVERALL EFFECT ON COLLAGEN
DEPOSITION IN MODELS OF FIBROSIS / N. Berghen* - J. Cremer - E. De Langhe - R. Lories
P111 TENOCYTES EXTRACTED FROM ROTATOR CUFF TENDONS INDUCE TNAP-DEPENDENT
MINERAL DEPOSITION AND EXPRESS GENES RELATED TO A HYPERTROPHIC
CHONDROCYTE DIFFERENTIATION / C. Darrieutort-Laffite* - P. Arnolfo - A. Najm - T. Garraud
- B. Le Goff - F. Blanchard
P112 STUDYING CELLULAR SENESCENCE IN HUMAN LYMPH NODE STROMAL CELLS DURING
THE EARLIEST PHASES OF RHEUMATOID ARTHRITIS / T. A. De Jong* - A. L. Timmerman -
J. F. Semmelink - J. S. Hähnlein - L. G. van Baarsen
P113 HUMAN LYMPH NODE STROMAL CELLS EXPRESS SELF-ANTIGENS TARGETED BY
ANTI-CITRULLINATED PROTEIN ANTYBODIES: ROLE FOR TOLERANCE INDUCTION IN
RHEUMATHOID ARTHRITIS / C. Grasso* - J. S. Hähnlein - R. Nadafi - T. A. De Jong -
T. H. Ramwadhdoebe - J. F. Semmelink - D. M. Gerlag - P. P. Tak - R. E. Mebius - M. Safy -
M. Maas - A. I. Catrina - H. Wähämaa - L. G. M. Van Baarsen
P114 TISSUE REGENERATION AND BONE REPAIR UPON TNF BLOCKADE IN EXPERIMENTAL
ARTHRITIS / K. Wanic - M. Kalkgruber - B. Niederreiter - T. Shvets - J. Smolen - S. Hayer*
P115 IMMUNOMODULATORY ACTIVITY OF ADIPOSE-DERIVED MESENCHYMAL STEM CELLS
OF ANKYLOSING SPONDYLITIS PATIENTS. / E. Kuca-Warnawin* - U. Skalska - I. Janicka -
K. Bonek - P. Głuszko - W. Maslinski - E. Kontny
P116 BASIC CHARACTERISTICS OF ADIPOSE-DERIVED MESENCHYMAL STEM CELLS OF
ANKYLOSING SPONDYLITIS PATIENTS / E. Kuca-Warnawin* - U. Skalska - M. Plebanczyk -
I. Janicka - U. Musialowicz - K. Bonek - P. Głuszko - E. Kontny
P117 VISFATIN DOWN-REGULATES GROWTH PROMOTING LNCRNA H19 DURING OSTEOGENIC
DIFFERENTIATION OF MESENCHYMAL STROMAL CELLS / D. M. Küppers - L. Tsiklauri -
M.-L. Hülser - K. Frommer* - S. Rehart - U. Müller-Ladner - E. Neumann
29POSTERS
THURSDAY 28 FEBRUARY 2019
18:00 - 19:30 POSTER TOURS Salon Pasteur
P118 PODOPLANIN REGULATES THE MIGRATION OF MESENCHYMAL STROMAL CELLS AND
THEIR INTERACTION WITH PLATELETS / L. Ward - L. Sheriff - J. Marshall - J. Manning -
G. Nash - H. M. McGettrick*
P119 EPIGENETIC REGULATION OF WNT SIGNALING IN SYSTEMIC SCLEROSIS VIA SFRP1 /
S. O’Reilly*
P120 IL-23 RECEPTOR SIGNALING IS IMPORTANT DURING PHYSIOLOGICAL BONE REMODELING
AND RADIAL BONE GROWTH THROUGH REGULATION OF OSTEOBLAST DIFFERENTIATION
/ W. Razawy - M. Schreuders-koedam - P. Asmawidjaja - A. Mus - H. Den Braanker - M. Oukka
- V. Kuchroo - B. Van der Eerden - E. Lubberts*
P121 MIR-146A AN IMPORTANT KEY PLAYER IN BONE METABOLISM / V. Saferding* - M. Hofmann
- J. S. Brunner - M. F. Militaru - A. Puchner - S. Hayer - M. Timmen - R. Stange - J. S. Smolen
- S. Blüml
P122 IMPORTANT ROLE OF DENDRITIC CELLS IN INFLAMMATORY ARTHRITIS / E. Simader* -
A. Puchner - V. Saferding - E. Goncalves-Alves - R. Pfeifle - G. Krönke - J. Smolen - S. Blüml
P123 EXTRACELLULAR MATRIX ATTENUATED MATRIX-DEGRADING EFFECTS OF VISFATIN
DURING ADIPOGENIC MSC DIFFERENTIATION / L. Tsiklauri* - J. Werner - K. Frommer -
S. Rehart - S. Wenisch - U. Müller-Ladner - E. Neumann
P124 OSTEOCYTE-DERIVED PODOPLANIN IS AN IMPORTANT REGULATOR OF BONE
REMODELLING IN THE KBXN SERUM TRANSFER MODEL OF RHEUMATOID ARTHRITIS /
C. Wehmeyer* - A. J. Naylor - K. Moeller - G. Poologasundarampillai - T. Pap - C. D. Buckley
NOVEL THERAPIES 1
Chair: Cem Gabay (CH)
P125 IL-36 AXIS IS AN EMERGING THERAPEUTIC TARGET IN PSORIATIC ARTHRITIS SYNOVIAL
TISSUE / M.-A. Boutet* - A. Nerviani - G. Lliso-Ribera - K. Goldmann - M. Lewis - C. Pitzalis
P126 MTOR BLOCKADE BY RAPAMYCIN DECREASES ARTHRITIS AND SPONDYLITIS
DEVELOPMENT AND SEVERITY IN HLA-B27 TRANSGENIC RATS / S. Chen* - M. Van Tok - V.
Knaup - L. Kraal - D. Pots - J. Taurog - D. Baeten - L. van Duivenvoorde -
M. van de Sande
P127 LUNG DISEASE IN SYSTEMIC JIA: AN EMERGING PROBLEM LINKED WITH YOUNG AGE
AND ANTI-IL-1/IL-6 / G. Chen* - V. Saper - G. Deutsch - R. P. Guillerman - K. Jagadeesh -
G. Schulert - S. Canna - Y. Lu - J. Birgmeier - A. Leung - A. Grom - G. Bejerano - M. Davis -
P. Khatri - E. Mellins
30POSTERS
THURSDAY 28 FEBRUARY 2019
18:00 - 19:30 POSTER TOURS Salon Pasteur
P128 AN ADD-ON TRAINING PROGRAM INVOLVING BREATHING EXERCISES, COLD EXPOSURE,
AND MEDITATION ATTENUATES INFLAMMATION AND DISEASE ACTIVITY IN AXIAL
SPONDYLOARTHRITIS – A PROOF OF CONCEPT TRIAL / H. De Jong - G. Buijze - M. Kox -
M. van de Sande* - D. J. van Schaardenburg - R. van Vugt - C. Popa - P. Picckers - D. Baeten
P130 PEFICITINIB TARGETS SYNOVIAL FIBROBLASTS IN RHEUMATOID ARTHRITIS / M. Diller* -
R. Hasseli - M.-L. Hülser - I. Aykara - S. Rehart - U. Müller-Ladner - E. Neumann
P131 TARGETING ACTIVATED SYNOVIAL FIBROBLASTS USING PHOTODYNAMIC THERAPY IN
HUMAN RHEUMATOID ARTHRITIS SYNOVIAL TISSUE / D. N. Dorst - M. Rijpkema -
M. Buitinga - P. Laverman - M. Brom - D. L. Bos - A. Freimoser-Grundschober - C. Klein -
B. Walgreen - P. M. Van der Kraan - M. Gotthardt - M. I. Koenders*
P132 EFFECTS OF RESVERATROL AND A NOVEL RESVERATROL-SALICYLATE HYBRID MOLECULE
ON ACTIVATION OF HUMAN CD4+ T CELLS / K. Goldhahn - J. Breitenbach* - F. Aldawsari -
C. Velazques-Martinez - B. Kloesch - K. Schmetterer - G. Steiner
P133 CLINICAL AND IMMUNOLOGICAL EFFECTS OF TOFACITINIB THERAPY IN RHEUMATOID
ARTHRITIS / A. Hamar* - A. Pusztai - E. Végh - Á. Horváth - K. Gulyás - S. Szamosi - Z. Pethő -
N. Bodnár - S. Szántó - G. Szűcs - A. Domján - G. Nagy - K. Hodosi - Z. Szekanecz
P134 SELECTIVE EXPANSION OF A THYMIC-DERIVED AND FUNCTIONALLY COMPETENT
REGULATORY T CELL POPULATION BY LOW-DOSE IL-2 THERAPY IN PATIENTS WITH
REFRACTORY SLE / J. Y. Humrich* - C. von Spee-Mayer - E. Siegert - M. Bertolo - A. Rose -
D. Abdirama - P. Enghard - B. Stuhlmüller - F. Hiepe - T. Alexander - E. Feist - A. Radbruch -
G.-R. Burmester - G. Riemekasten
P135 SIGLEC-15 AS A POTENTIAL TARGET FOR THE TREATMENT OF BONE LOSS DURING
INFLAMMATORY ARTHRITIS / M.A. Korn* - H. Schmitt - M. Seeling - U. Lux - T. Winkler -
F. Nimmerjahn - L.Nitschke
NOVEL THERAPIES 2
Chair: Douglas Veale (IR)
P136 THE EFFECTS OF LY294002, THE PHOSPHOINOSITIDE 3-KINASE INHIBITOR, ON
NEUTROPHIL APOPTOSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND COLLAGEN-
INDUCED ARTHRITIS IN MICE / X. Huang - T. Li* - S. Zheng - W. Deng - Y. Huang - Z. Huang
- Q. Huang - Z. Huang
P138 INVESTIGATING GENE EXPRESSION PATTERNS AND FUNCTION OF TOLEROGENIC
DENDRITIC CELLS / L. Nwosu* - K. Smith - C. Hilkens - J. Isaacs
P140 IDENTIFICATION OF AFFIMERS THAT BIND TO THE IL-7R AND INHIBITS THE IL-7 SIGNALLING
CASCADE / D. Perez-Witzke - C. Tiede - J. I. Robinson - D. Tomlinson - P. Emery - F. Ponchel*
31POSTERS
THURSDAY 28 FEBRUARY 2019
18:00 - 19:30 POSTER TOURS Salon Pasteur
P141 DIFFERENTIAL DNA METHYLATION IN PERIPHERAL NAÏVE CD4+T-CELLS IN EARLY
RHEUMATOID ARTHRITIS PATIENTS / R. Pitaksalee* - A. N. Burska - I. McInnes - P. Emery -
R. Hodgett - F. Ponchel
P142 ROS101, A NOVEL TARGETED METHOTREXATE PRODRUG, SELECTIVELY ACTIVATED BY
REACTIVE OXYGEN SPECIES (ROS) SHOWS REDUCED TOXICITY IN RAT CIA MODEL OF
RHEUMATOID ARTHRITIS / V. Previtali* - N. Woodworth - M. H. Hopkins - J. H. Petersen -
I. Ahnfelt-Rønne - M. H. Clausen
P144 EFFECT OF LOW-DOSE IONIZING RADIATION ON THE INFLAMMATORY PHENOTYPE OF
ADIPOCYTES AND DIFFERENTIATION OF OSTEOCLASTS (IN VITRO) / K. Shreder* - F. Rapp -
D. Kraft - S. Hassan - C. Fournier
P145 HCQ ALLEVIATES 5-FU-INDUCED INTESTINAL INFLAMMATION THROUGH INHIBITING
TLR9-DEPENDENT DNA SENSING PATHWAY / X. Li - Y. Sun - J. Zhang - J. He - C. Yu - H. Jie
- E. Sun*
P146 GOLIMUMAB IN RHEUMATOID AND PSORIATIC ARTHRITIS. THE RELATIONSHIP BETWEEN
MINIMUM SERUM CONCENTRATION, ANTI-GOLIMUMAB ANTIBODIES AND ACTIVITY OF
DISEASE / J. Uceda* - M. J. Fobelo - R. Hernandez
P147 TREATMENT WITH USTEKINUMAB IN PSORIASIC ARTHRITIS IN CONDITIONS OF REAL
CLINICAL PRACTICE / J. Uceda* - R. Hernandez - J. L. Marenco
SYSTEMIC EFFECTS OF INFLAMMATION 1
Chair: Frederique Ponchel (UK)
P148 JAK-INHIBITION BY BARICITINIB AND TOFACITINIB AMELIORATES PATHOLOGICAL BONE
LOSS / S. Adam* - N. Simon - U. Steffen - F. Andes - D. Müller - S. Culemann - D. Andreev -
M. Hahn - C. Scholtysek - G. Schett - G. Krönke - S. Frey - A. Hueber
P149 HIGHER EXPRESSION OF SIGLEC-7/9 ON GRANULOCYTES AND MONOCYTES HAS A
PROTECTIVE ROLE IN RHEUMATOID ARTHRITIS / F. Andes* - J. Zapf - J. Hahn - B. Manger -
G. Schett - U. Steffen
P150 IMPACT OF RADON SPA ON PAIN AND THE IMMUNE SYSTEM OF PATIENTS WITH
MUSCULOSKELETAL DISORDERS / I. Becker* - A.-J. Donaubauer - G. Klein - C. Fournier -
R. Fietkau - B. Frey - U. S. Gaipl
P151 NOCICEPTIVE PAIN IN ACUTE EXPERIMENTAL SYNOVITIS IS PARTLY MEDIATED BY THE
ALARMIN S100A9 / A. B. Blom - M. H. van den Bosch - E. J. Geven - E. N. Blaney Davidson -
P. M. van der Kraan - P. L. van Lent*
32POSTERS
THURSDAY 28 FEBRUARY 2019
18:00 - 19:30 POSTER TOURS Salon Pasteur
P152 INTERFERON-I ACTIVITY IN EARLY AND ESTBLISHED RHEUMATOID ARTHRITIS (RA) WITH
AND WITHOUT CARDIOVASCULAR ABNORMALITIES IN CARDIAC MAGNETIC RESONANCE
(CMR) / A. N. Burska* - G. Harrison - Y. El-Sherbiny - L.-A. Bissell - A. Giollo - E. M. Hensor -
G. Fent - B. Erhayiem - J. Greenwood - S. Plein - J. Andrews - E. Vital - M. H. Buch
P154 LOCAL LOW DOSE RADIATION INDUCES SYSTEMIC IMMUNE ALTERATIONS IN TWO
EXPERIMENTAL MODELS OF INFLAMMATORY ARTHRITIS / L. Deloch* - M. Rückert -
M. Seeling - F. Nimmerjahn - R. Fietkau - B. Frey - U. S. Gaipl
P155 IMMO-LDRT01 TRIAL: IMMUNOMODULATORY EFFECTS OF LOW DOSE RADIATION
THERAPY OF CHRONIC DEGENERATIVE AND INFLAMMATORY DISEASES /
A.-J. Donaubauer* - T. Gryc - I. Becker - O. J. Ott - R. Fietkau - U. S. Gaipl - B. Frey
P156 SYSTEMIC INFLAMMATION ORIGINATING FROM THE SKIN OR THE INTESTINE COMBINED
WITH BIOMECHANICAL STRESS HAS DIFFERENT EFFECTS ON THE JOINTS IN AN IN VIVO
MOUSE MODEL / G. R. Gulino* - M. Van Mechelen - R. Lories
P157 RADIORESISTANT AND RADIOSENSITIVE CELLS CONTRIBUTE TO IL-18BP PRODUCTION IN
A MODEL OF MACROPHAGE ACTIVATION SYNDROME / M. Harel* - E. Rodriguez -
C. Girard-Guyonvarc’h - G. Palmer - C. Gabay
P158 PATHOLOGICAL INFLAMMATION IN EXPERIMENTAL SPONDYLOARTHRITIS IS
CHARACTERIZED BY HIGH ENDOTHELIAL VENULES AND ECTOPIC LYMPHOID
STRUCTURES IN THE BONE MARROW / M. H. Kaaij* - J. P. van Hamburg - J. Rip - G. Kollias
- D. L. Baeten - M. Nolte - L. M. van Duivenvoorde - S. W. Tas
P159 OLT1177™, AN ORAL NLRP3 INFLAMMASOME INHIBITOR, INHIBITS ACUTE JOINT
INFLAMMATION AND CIRCULATING IL-1 DURING GOUT FLARES IN HUMANS / V. Klück*
- M. Janssen - T. L. Jansen - I. W. Tengesdal - K. Schraa - D. B. Skouras - C. Marchetti -
C. A. Dinarello - L. A. Joosten
P160 THE FIRST PHASE 2A PROOF-OF-CONCEPT STUDY OF A SELECTIVE NLRP3 INFLAMMASOME
INHIBITOR, DAPANSUTRILE™ (OLT1177™), IN ACUTE GOUT / T. L. Jansen - V. Klück* -
M. Janssen - A. Comarniceanu - M. Efdé - C. L. Scribner - R. B. Barrow - D. B. Skouras -
C. A. Dinarello - L. A. Joosten
P161 THE RELATION BETWEEN THE INFLAMMATORY STATUS OF HUMAN END STAGE OA
SYNOVIUM AND LEVELS OF LOW DENSITY LIPOPROTEIN / N. Kruisbergen -
M. van den Bosch - A. Blom - P. van Lent*
P162 EXTRACELLULAR VESICLES FROM PATIENTS WITH ANKYLOSING SPONDYLITIS CONVEY
PROTEINS RELATED TO IMMUNE RESPONSE: NEW SIGNALING PATHWAYS? / Y. Huang -
T. Li* - S. Zheng - X. Huang - Q. Huang - W. Deng
33POSTERS
THURSDAY 28 FEBRUARY 2019
18:00 - 19:30 POSTER TOURS Salon Pasteur
SYSTEMIC EFFECTS OF INFLAMMATION 2
Chair: Hubert Marotte (FR)
P163 EFFECT OF HIGH FAT DIET ON SYSTEMIC AND LOCAL INFLAMMATION IN THE CONTEXT
OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS MOUSE MODELS /
H. M. Sauermilch* - M.-L. Hülser - C. Schreiyäck - Y. Luo - A. Bozec - G. Schett -
U. Müller-Ladner - E. Neumann
P164 PORPHYROMONAS GINGIVALIS EXPERIMENTALLY INDUCES PERIODONTIS AND AN ANTI-
CCP2-ASSOCIATED ARTHRITIS IN THE RAT / G. Courbon - M. Rinaudo-Gaujous -
V. Blasco-Baque - I. Auger - R. CAIRE - L. Mijola - L. Vico - S. Paul - H. Marotte*
P165 MOLECULAR AND CELLULAR BIOMARKERS THAT DISCRIMINATE JUVENILE IDIOPATHIC
ARTHRITIS FROM SEPTIC ARTHRITIS / N. Nziza* - M. Cren - A. Carbasse - P. Mahe -
M. Delpont - D. Sabah - H. Chevassus - M. Khalil - T. Mura - C. Jorgensen - P. Plence -
E. Jeziorski - I. Duroux-Richard - F. Apparailly
P166 IMPACT OF DISEASE ACTIVITY, DURATION AND MUSCLE INVOLVEMENT ON CHANGES OF
BODY COMPOSITION IN MYOSITIS PATIENTS / S. Oreska* - M. Spiritovic - P. Cesak -
O. Marecek - H. Storkanova - H. Smucrova - B. Hermankova - K. Kubinova - M. Klein -
L. Vernerova - O. Ruzickova - K. Pavelka - L. Senolt - H. Mann - J. Vencovsky - M. Tomcik
P167 ASSOCIATION OF CHANGES OF BODY COMPOSITION IN SCLERODERMA PATIENTS
WITH DISEASE ACTIVITY, PHYSICAL ACTIVITY AND SERUM LEVELS OF INFLAMMATORY
CYTOKINES / S. Oreska* - M. Spiritovic - P. Cesak - M. Cesak - H. Storkanova - H. Smucrova
- B. Hermankova - O. Ruzickova - H. Mann - K. Pavelka - L. Senolt - J. Vencovsky - R. Becvar
- M. Tomcik
P168 PREVALENCE AND CHARACTERISTICS OF CARDIOVASCULAR RISK FACTORS AND
CORONARY DISEASE AMONG PATIENTS WITH PSORIATIC ARTHRITIS / N. Plaza Aulestia* -
S. A. Rodriguez Montero - M. J. Perez Quintana - M. L. Velloso Feijóo
P169 EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR ON HUMAN MACROPHAGES
FROM ARTHRITIS PATIENTS / T. Rakovich* - C. Cunningham - S. Ansboro - T. McGarry -
D. J. Veale - U. Fearon
P170 POTENTIAL ROLE FOR THE CHEMOKINE CCL22 IN THE DEVELOPMENT AND EARLY
PROGRESSION OF RHEUMATOID ARTHRITIS / B. Réthi* - A. Krishnamurthy - A. Circiumaru
- K. Sakurabas - V. Joshua - M. Sun - C. Szu-Ying - M. Engström - H. Wähämaa - A. Hensvold -
J. E. Smith - A. I. Catrina
P171 HSP90 IN AXIAL SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS AND RHEUMATOID
ARTHRITIS / H. Storkanova* - K. Bubova - S. Oreska - M. Spiritovic - B. Hermankova -
M. Gregorova - K. Mintalova - J. Horinkova - K. Pavelka - J. Vencovsky - J. Stolfa - M. Husakova
- S. Forejtova - L. Senolt - M. Tomcik
34You can also read
